Drug companies should release data from all trials of licensed drugs, say MPsBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f321 (Published 16 January 2013) Cite this as: BMJ 2013;346:f321
- Nigel Hawkes
The drug industry should be obliged to release in a publicly accessible form all the information it possesses about trials of licensed drugs, the House of Commons Health Committee has said in a new report on the functioning of the National Institute for Health and Clinical Excellence (NICE).1
It should be “neither legal nor ethical” to withhold such data, said the committee. It was concerned that failure to observe this simple principle undermined the effectiveness of NICE, because the institute was forced to appraise drugs without having access to all relevant data.
“This situation cannot be allowed to continue,” said Stephen Dorrell MP, the Conservative chairman of the Health Committee. At a press conference in London to launch the report he called for …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial